Evidence map›Paper›PMID 36378563›Full record

ReviewReviews in medical virology2023

Indirect effects of cytomegalovirus infection: Implications for vaccine development.

Philip Moseley, Paul Klenerman, Seilesh Kadambari

Open access · hybridAbstract readReview
In one paragraph

Review in Reviews in medical virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. A bibliometric analysis of vaccination against atherosclerosis.Human vaccines & immunotherapeutics · 2024
    Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Philip MoseleyDepartment of Paediatrics, Horton General Hospital, Oxford University Hospitals, Banbury, UK.
Paul KlenermanTranslational Gastroenterology Unit, University of Oxford, Oxford, UK.
Seilesh KadambariDepartment of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, UK.ORCID 0000-0003-3658-7635
Great Ormond Street Hospital · GBHorton General Hospital · GBUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Development of a cytomegalovirus (CMV) vaccine is a high priority due to its significant global impact-contributing to mortality in immunosuppressed individuals, neurodevelopmental delay in infected neonates and non-genetic sensorineural hearing loss. The impact of CMV on the general population has been less well studied; however, a wide range of evidence indicates that CMV may increase the risk of atherosclerosis, cancer, immunosenescence, and progression of tuberculosis (TB) and human immunodeficiency virus. Due to the high seroprevalence of CMV worldwide, any modulation of risk by CMV is likely to have a significant impact on the epidemiology of these diseases. This review will evaluate how CMV may cause morbidity and mortality outside of the neonatal and immunosuppressed populations and consider the potential impact of a CMV vaccine on these outcomes.

Indexed as

Cytomegalovirus InfectionsCytomegalovirus VaccinesHumansInfant, NewbornSeroepidemiologic StudiesVaccine DevelopmentCytomegalovirus Vaccines

Identifiers

PMID36378563
PMCPMC10078107
OpenAlexW4309100412

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.